Sunovion’s Parkinson’s Candidate Hits PIII Primary Endpoint, US Filing Set for Spring

Sunovion Pharmaceuticals said on January 29 that its Parkinson’s disease treatment APL-130277 (apomorphine) beat the primary endpoint in a US PIII study gauging its efficacy for “off” episodes. Data will support the company’s planned FDA submission in this spring, it...read more